PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
ConclusionCombined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - March 18, 2024 Category: Cancer & Oncology Source Type: research
Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies
CONCLUSIONS: There exisits an association between PLR and tumor response as well as survival outcomes in patients receiving immunotherapy, particularly those treated with the combination of bevacizumab and anti-PD-1.PMID:38492340 | DOI:10.1016/j.intimp.2024.111863 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 16, 2024 Category: Allergy & Immunology Authors: Zi-Yi Wang Bin Xu Lu-Na Wang Xiao-Dong Zhu Cheng Huang Ying-Hao Shen Hui Li Mei-Ling Li Jian Zhou Jia Fan Hui-Chuan Sun Source Type: research
Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies
CONCLUSIONS: There exisits an association between PLR and tumor response as well as survival outcomes in patients receiving immunotherapy, particularly those treated with the combination of bevacizumab and anti-PD-1.PMID:38492340 | DOI:10.1016/j.intimp.2024.111863 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 16, 2024 Category: Allergy & Immunology Authors: Zi-Yi Wang Bin Xu Lu-Na Wang Xiao-Dong Zhu Cheng Huang Ying-Hao Shen Hui Li Mei-Ling Li Jian Zhou Jia Fan Hui-Chuan Sun Source Type: research
Disease control in patients with non ‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy
ConclusionsOur findings indicated that maintaining the dose of PEM after the second treatment cycle in patients with NSCLC, along with concurrent use of Bev and the presence of TTF-1 positivity, could enhance disease control rates and extend survival. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 15, 2024 Category: Cancer & Oncology Authors: Yutaka Takahara,
Ryudai Abe,
Nagae Sumito,
Takuya Tanaka,
Yoko Ishige,
Ikuyo Shionoya,
Kouichi Yamamura,
Kazuaki Nishiki,
Masafumi Nojiri,
Ryo Kato,
Shohei Shinomiya,
Taku Oikawa Tags: ORIGINAL ARTICLE Source Type: research
Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses
ConclusionThe ATZ/BVC combination is an expensive targeted immunotherapy in AHCC. Significant discounts in ATZ and BVC prices are essential for this novel approach to be cost-effective and extensively used. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - March 15, 2024 Category: Cancer & Oncology Source Type: research
Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study
CONCLUSIONS: The combination of HAIC, a PD-1 inhibitor, and bevacizumab shows potential for advanced GBC with hepatic oligometastasis. The therapeutic response of hepatic metastasis had a greater influence on prognosis than that of primary gallbladder lesions.PMID:38482216 | PMC:PMC10932672 | DOI:10.21037/jgo-23-816 (Source: Cancer Control)
Source: Cancer Control - March 14, 2024 Category: Cancer & Oncology Authors: Wenchao Zhao Zhiyuan Yao Jingbo Li Wenping Li Qi Dou Xiangfei Zhao Yintao Wu Nianxin Xia Source Type: research
Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant
ConclusionWe describe nine patients with HCC outside Milan with inadequate response with liver-directed therapy, who achieved marked responses with CPIT, allowing for consideration of successful liver transplantation. Our case series supports the consideration of locoregional therapies and CPIT for downstaging to within transplant criteria. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - March 14, 2024 Category: Cancer & Oncology Source Type: research
Hepatocellular Carcinoma: Advances in Systemic Therapy
This article reviews the evolving landscape of systemic therapies for advanced HCC, emphasizing recent advancements and their impact on patient outcomes. The advent of molecular targeted therapies has transformed HCC management, with sorafenib being the first FDA-approved molecular targeted therapy, setting a standard for a decade. However, recent breakthroughs involve the combination of atezolizumab and bevacizumab, demonstrating superior outcomes over sorafenib, leading to FDA approval in 2020. Another notable combination is tremelimumab and durvalumab, showing efficacy in a multinational phase III trial. Beyond these co...
Source: Seminars in Interventional Radiology - March 14, 2024 Category: Radiology Authors: Selene, Insija Ilyas Ozen, Merve Patel, Reema A. Tags: Review Article Source Type: research
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
ConclusionsNo significant differences in efficacy and safety were observed with PH. Prophylactic treatment for varices before the start of Atezo + Beva would allow treatment to continue relatively safely. (Source: Cancer Medicine)
Source: Cancer Medicine - March 13, 2024 Category: Cancer & Oncology Authors: Takahiro Kinami,
Shinsuke Uchikawa,
Tomokazu Kawaoka,
Shintaro Yamasaki,
Masanari Kosaka,
Yusuke Johira,
Shigeki Yano,
Kei Amioka,
Kensuke Naruto,
Kenji Yamaoka,
Yasutoshi Fujii,
Hatsue Fujino,
Takashi Nakahara,
Atsushi Ono,
Eisuke Murakami, Tags: RESEARCH ARTICLE Source Type: research
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
CONCLUSION: In patients with BM from EGFR-mutated NSCLC, cerebral radiotherapy with bevacizumab markedly improved OS. This improvement was more evident after cerebral radiotherapy.PMID:38478262 | DOI:10.1007/s12094-024-03418-3 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Yuanliang Zhou Jingchao Li Yankang Li Guangchuan Deng Qi Wang Hongyue Qin Jianbin Li Zhenxiang Li Source Type: research
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
ConclusionIn patients with BM from EGFR-mutated NSCLC, cerebral radiotherapy with bevacizumab markedly improved OS. This improvement was more evident after cerebral radiotherapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research
Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins
Inducing the degradation of pathological soluble antigens could be the key to greatly enhancing the efficacy of therapeutic monoclonal antibodies (mAbs), extensively used in the treatment of autoimmune and inflammatory disorders or cancer. Lysosomal targeting has gained increasing interest in recent years due to its pharmaceutical applications far beyond the treatment of lysosomal diseases, as a way to address proteins to the lysosome for eventual degradation. Mannose 6-phosphonate derivatives (M6Pn), called AMFA, are unique glycovectors that can significantly enhance the cellular internalization of the proteins conjugated...
Source: Frontiers in Immunology - March 12, 2024 Category: Allergy & Immunology Source Type: research
